Solara Active Pharma Sciences Ltd
Solara Active Pharma Sciences Ltd is engaged in business of manufacturing, production, processing, formulating, sale, import, export, merchandising, distributing, trading of APIs.[1]
It was formed through demerger of API business from Strides Shasun Ltd (currently named as Stride Pharma Sciences). Subsequently, it also acquired the human API business from Sequent Scientific Ltd during the same time, making it a pure play API company.[2]
- Market Cap ₹ 2,986 Cr.
- Current Price ₹ 625
- High / Low ₹ 712 / 422
- Stock P/E 699
- Book Value ₹ 346
- Dividend Yield 0.00 %
- ROCE 4.86 %
- ROE -0.13 %
- Face Value ₹ 10.0
Pros
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -3.27% over past five years.
- Company has a low return on equity of -12.0% over last 3 years.
- Promoters have pledged 37.1% of their holding.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE 1000 BSE Healthcare
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|
| 521 | 1,387 | 1,322 | 1,617 | 1,268 | 1,444 | 1,289 | 1,284 | 1,369 | 1,431 | |
| 464 | 1,174 | 1,062 | 1,231 | 1,188 | 1,309 | 1,384 | 1,077 | 1,182 | 1,240 | |
| Operating Profit | 57 | 213 | 260 | 386 | 81 | 134 | -95 | 206 | 187 | 192 |
| OPM % | 11% | 15% | 20% | 24% | 6% | 9% | -7% | 16% | 14% | 13% |
| 2 | 12 | 27 | 29 | 16 | 22 | -185 | 8 | 0 | 2 | |
| Interest | 25 | 82 | 78 | 84 | 75 | 90 | 105 | 115 | 95 | 92 |
| Depreciation | 34 | 83 | 94 | 109 | 112 | 111 | 103 | 99 | 100 | 103 |
| Profit before tax | 0 | 60 | 115 | 222 | -91 | -45 | -488 | 1 | -7 | -2 |
| Tax % | -70% | 1% | 0% | 0% | -36% | -50% | 16% | 0% | 0% | |
| 0 | 59 | 115 | 221 | -58 | -22 | -567 | 1 | -7 | -2 | |
| EPS in Rs | 17.30 | 32.01 | 46.22 | -12.11 | -4.62 | -118.21 | 0.15 | -2.05 | -1.55 | |
| Dividend Payout % | 0% | 22% | 5% | 11% | 0% | -49% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -3% |
| 3 Years: | -2% |
| TTM: | 15% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 25% |
| TTM: | -83% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -17% |
| 3 Years: | 22% |
| 1 Year: | -2% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | -7% |
| 3 Years: | -12% |
| Last Year: | 0% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 25 | 26 | 27 | 36 | 36 | 36 | 36 | 40 | 45 |
| Reserves | 739 | 930 | 1,059 | 1,553 | 1,489 | 1,464 | 898 | 1,054 | 1,208 |
| 633 | 538 | 722 | 621 | 1,037 | 1,013 | 1,012 | 796 | 687 | |
| 425 | 466 | 346 | 404 | 383 | 386 | 406 | 342 | 393 | |
| Total Liabilities | 1,821 | 1,960 | 2,153 | 2,614 | 2,945 | 2,899 | 2,351 | 2,232 | 2,333 |
| 1,086 | 1,218 | 1,397 | 1,382 | 1,356 | 1,364 | 1,268 | 1,193 | 1,238 | |
| CWIP | 71 | 40 | 40 | 88 | 239 | 238 | 256 | 280 | 205 |
| Investments | 1 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 5 |
| 663 | 701 | 716 | 1,144 | 1,350 | 1,295 | 825 | 757 | 886 | |
| Total Assets | 1,821 | 1,960 | 2,153 | 2,614 | 2,945 | 2,899 | 2,351 | 2,232 | 2,333 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| 49 | 166 | 242 | 155 | -242 | 156 | 109 | 213 | 153 | |
| -85 | -113 | -359 | -106 | -243 | -81 | -4 | -37 | -99 | |
| 68 | -23 | 97 | 92 | 334 | -113 | -106 | -180 | -54 | |
| Net Cash Flow | 31 | 30 | -20 | 142 | -151 | -38 | -0 | -4 | 1 |
| Free Cash Flow | 14 | 108 | -25 | -16 | -451 | 46 | 69 | 173 | 101 |
| CFO/OP | 92% | 85% | 103% | 49% | -277% | 106% | -113% | 104% | 83% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 184 | 76 | 63 | 109 | 141 | 136 | 99 | 93 | 117 |
| Inventory Days | 252 | 111 | 170 | 149 | 321 | 258 | 163 | 185 | 170 |
| Days Payable | 420 | 127 | 132 | 156 | 154 | 142 | 142 | 145 | 146 |
| Cash Conversion Cycle | 16 | 60 | 101 | 102 | 308 | 252 | 120 | 133 | 140 |
| Working Capital Days | -124 | -22 | -32 | 16 | 37 | 20 | -128 | -62 | -23 |
| ROCE % | 10% | 12% | 15% | -0% | 2% | -9% | 6% | 5% |
Insights
In beta| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| R&D Spend (charged to P&L) INR Crores ・Standalone data |
|
||||||||
| Number of Countries Served count |
|||||||||
| Cumulative DMFs Filed count |
|||||||||
| Number of Permanent Employees count ・Standalone data |
|||||||||
| Number of Products Commercialized count |
|||||||||
| Regulated Market Revenue Share % of total revenue |
|||||||||
| Total Reactor Capacity KL |
|||||||||
Extracted by Screener AI
Documents
Announcements
-
Conversion Of Partly Paid-Up Rights Equity Shares Into Fully Paid-Up Equity Shares In Relation To The Rights Issue By The Company, Upon Receipt Of The Call Monies, As Applicable
- 2,79,582 partly paid rights shares converted to fully paid on August 19, 2026.
-
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
- Solara Active Pharma Sciences Limited has informed regarding allotment of 2250 equity shares pursuant to exercise of ESOP options
-
Update With Respect To Our Intimation Dated July 23, 2026, Regarding Appointment Of CIO And SMP Of The Company.
- Ajit Manocha’s CIO and SMP appointment date revised from August 10, 2026 to August 17, 2026.
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
- Transcript of Earnings Conference call pertaining to financial results of the Company for the quarter ended June 30, 2026
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Solara Active Pharma Sciences Limited has informed about the copy of the Newspaper publication providing extract of the unaudited Financial Results (Standalone and Consolidated) ....
Annual reports
Concalls
-
Jul 2026Transcript PPT REC
-
May 2026Transcript PPT REC
-
Feb 2026Transcript PPT REC
-
Nov 2025Transcript PPT REC
-
Jul 2025Transcript PPT REC
-
May 2025TranscriptPPTREC
-
Jan 2025Transcript PPT REC
-
Oct 2024Transcript PPT REC
-
Jul 2024TranscriptPPTREC
-
Jun 2024TranscriptPPTREC
-
Feb 2024TranscriptPPTREC
-
Nov 2023TranscriptPPTREC
-
Aug 2023TranscriptPPTREC
-
May 2023TranscriptPPT
-
Feb 2023TranscriptPPT
-
Nov 2022TranscriptPPT
-
Aug 2022TranscriptPPT
-
May 2022Transcript PPT
-
Jul 2021TranscriptPPT
-
Apr 2021Transcript PPT
-
Jan 2021TranscriptPPT
-
Oct 2020TranscriptPPT
-
Sep 2020TranscriptPPT
-
May 2020Transcript PPT
-
Jan 2020TranscriptPPT
-
Oct 2019TranscriptPPT
-
Aug 2019TranscriptPPT
-
May 2019TranscriptPPT
-
Jan 2019TranscriptPPT
-
Nov 2018TranscriptPPT
-
Jul 2018TranscriptPPT
Product Offerings
The company is a pure-play API manufacturer, offering a range of high-value commercial APIs and contract manufacturing services across 73+ countries. Its portfolio includes 60+ commercial APIs across key therapeutic segments, including anthelmintic, anti-malaria, anti-infective, etc. The top 10 molecules contribute to 84% of its total revenues. [1] [2] [3]